Skip to main content

Table 2 Antidiabetic drugs prior to administration of DPP-4 inhibitors

From: Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

Antidiabetic drugs

Sitagliptin

Vildagliptin

Teneligliptin

Alogliptin

Linagliptin

Insulin

145 (16.5%)

26 (10.3%)

55 (21.2%)

8 (3.4%)

30 (16.7%)

Sulphonylurea

333 (37.9%)

69 (27.3%)

36 (13.9%)

71 (30%)

30 (16.7%)

Biguanide

275 (31.3%)

63 (24.9%)

36 (13.9%)

49 (20.7%)

34 (18.9%)

Alpha-glucosidase inhibitor

189 (21.5%)

43 (17%)

22 (8.5%)

46 (19.4%)

15 (8.3%)

Thiazolidinedione

102 (11.6%)

21 (8.3%)

7 (2.7%)

51 (21.5%)

4 (2.2%)

Glinide

75 (8.5%)

21 (8.3%)

10 (3.9%)

11 (4.6%)

15 (8.3%)

SGLT2 inhibitor

5 (0.6%)

2 (0.8%)

10 (3.9%)

0 (0%)

3 (1.7%)

Nothing

251 (28.6%)

99 (39.1%)

145 (55.8%)

93 (39.2%)

89 (49.4%)

  1. DPP-4 dipeptidyl-peptidase 4, SGLT2 sodium glucose co-transporter 2